Literature DB >> 27179313

Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease.

Keith S Cover1, Ronald A van Schijndel2, Adriaan Versteeg2, Kelvin K Leung3, Emma R Mulder2, Remko A Jong2, Peter J Visser2, Alberto Redolfi4, Jerome Revillard5, Baptiste Grenier5, David Manset5, Soheil Damangir6, Paolo Bosco4, Hugo Vrenken2, Bob W van Dijk2, Giovanni B Frisoni7, Frederik Barkhof2.   

Abstract

The purpose of this study is to assess the reproducibility of hippocampal atrophy rate measurements of commonly used fully-automated algorithms in Alzheimer disease (AD). The reproducibility of hippocampal atrophy rate for FSL/FIRST, AdaBoost, FreeSurfer, MAPS independently and MAPS combined with the boundary shift integral (MAPS-HBSI) were calculated. Back-to-back (BTB) 3D T1-weighted MPRAGE MRI from the Alzheimer's Disease Neuroimaging Initiative (ADNI1) study at baseline and year one were used. Analysis on 3 groups of subjects was performed - 562 subjects at 1.5T, a 75 subject group that also had manual segmentation and 111 subjects at 3T. A simple and novel statistical test based on the binomial distribution was used that handled outlying data points robustly. Median hippocampal atrophy rates were -1.1%/year for healthy controls, -3.0%/year for mildly cognitively impaired and -5.1%/year for AD subjects. The best reproducibility was observed for MAPS-HBSI (1.3%), while the other methods tested had reproducibilities at least 50% higher at 1.5T and 3T which was statistically significant. For a clinical trial, MAPS-HBSI should require less than half the subjects of the other methods tested. All methods had good accuracy versus manual segmentation. The MAPS-HBSI method has substantially better reproducibility than the other methods considered.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer disease; Atrophy; Automatic segmentation; Boundary shift integral; Hippocampus; Magnetic resonance imaging; Manual segmentation; Mild cognitive impairment

Mesh:

Year:  2016        PMID: 27179313     DOI: 10.1016/j.pscychresns.2016.04.006

Source DB:  PubMed          Journal:  Psychiatry Res Neuroimaging        ISSN: 0925-4927            Impact factor:   2.376


  12 in total

1.  Small Vessel Disease on Neuroimaging in a 75-Year-Old Cohort (PIVUS): Comparison With Cognitive and Executive Tests.

Authors:  Ruta Nylander; Lena Kilander; Håkan Ahlström; Lars Lind; Elna-Marie Larsson
Journal:  Front Aging Neurosci       Date:  2018-07-16       Impact factor: 5.750

Review 2.  Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI.

Authors:  Houshang Amiri; Alexandra de Sitter; Kerstin Bendfeldt; Marco Battaglini; Claudia A M Gandini Wheeler-Kingshott; Massimiliano Calabrese; Jeroen J G Geurts; Maria A Rocca; Jaume Sastre-Garriga; Christian Enzinger; Nicola de Stefano; Massimo Filippi; Álex Rovira; Frederik Barkhof; Hugo Vrenken
Journal:  Neuroimage Clin       Date:  2018-04-26       Impact factor: 4.881

3.  Non-linear registration improves statistical power to detect hippocampal atrophy in aging and dementia.

Authors:  F Bartel; M Visser; M de Ruiter; J Belderbos; F Barkhof; H Vrenken; J C de Munck; M van Herk
Journal:  Neuroimage Clin       Date:  2019-06-18       Impact factor: 4.881

4.  Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods.

Authors:  A de Sitter; M Visser; I Brouwer; K S Cover; R A van Schijndel; R S Eijgelaar; D M J Müller; S Ropele; L Kappos; Á Rovira; M Filippi; C Enzinger; J Frederiksen; O Ciccarelli; C R G Guttmann; M P Wattjes; M G Witte; P C de Witt Hamer; F Barkhof; H Vrenken
Journal:  Eur Radiol       Date:  2019-11-05       Impact factor: 5.315

5.  Hippocampo-Horn Percentage and Parietal Atrophy Score for Easy Visual Assessment of Brain Atrophy on Magnetic Resonance Imaging in Early- and Late-Onset Alzheimer's Disease.

Authors:  David Silhan; Olga Pashkovska; Ales Bartos
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

6.  Immune and Imaging Correlates of Mild Cognitive Impairment Conversion to Alzheimer's Disease.

Authors:  Francesca La Rosa; Marina Saresella; Francesca Baglio; Federica Piancone; Ivana Marventano; Elena Calabrese; Raffaello Nemni; Enrico Ripamonti; Monia Cabinio; Mario Clerici
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

Review 7.  Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

Authors:  Mara Ten Kate; Silvia Ingala; Adam J Schwarz; Nick C Fox; Gaël Chételat; Bart N M van Berckel; Michael Ewers; Christopher Foley; Juan Domingo Gispert; Derek Hill; Michael C Irizarry; Adriaan A Lammertsma; José Luis Molinuevo; Craig Ritchie; Philip Scheltens; Mark E Schmidt; Pieter Jelle Visser; Adam Waldman; Joanna Wardlaw; Sven Haller; Frederik Barkhof
Journal:  Alzheimers Res Ther       Date:  2018-10-30       Impact factor: 6.982

8.  Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment.

Authors:  Neus Falgàs; Raquel Sánchez-Valle; Núria Bargalló; Mircea Balasa; Guadalupe Fernández-Villullas; Beatriz Bosch; Jaume Olives; Adrià Tort-Merino; Anna Antonell; Cristina Muñoz-García; María León; Oriol Grau; Magdalena Castellví; Nina Coll-Padrós; Lorena Rami; Alberto Redolfi; Albert Lladó
Journal:  Neuroimage Clin       Date:  2019-07-05       Impact factor: 4.881

9.  Assessment of longitudinal hippocampal atrophy in the first year after ischemic stroke using automatic segmentation techniques.

Authors:  Mohamed Salah Khlif; Emilio Werden; Natalia Egorova; Marina Boccardi; Alberto Redolfi; Laura Bird; Amy Brodtmann
Journal:  Neuroimage Clin       Date:  2019-10-22       Impact factor: 4.881

10.  The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale.

Authors:  David Silhan; Ales Bartos; Jana Mrzilkova; Olga Pashkovska; Ibrahim Ibrahim; Jaroslav Tintera
Journal:  Curr Alzheimer Res       Date:  2020       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.